Rep. Pingree Among 75 Plus Members of Congress Urging Congressional Leadership to Lower Insulin Prices for Uninsured

WASHINGTON, Aug. 5 -- Rep. Chellie Pingree, D-Maine, issued the following news release and a July 29, 2022, letter:

Congresswoman Chellie Pingree (D-Maine) and more than 75 members of Congress called on congressional leadership to include people without health insurance in any legislation that limits out-of-pocket costs for insulin.

In their letter to Speaker Pelosi, Senate Majority Leader Schumer, House Minority Leader McCarthy, and Senate Minority Leader McConnell, Pingree and her colleagues--led by Congressional Progressive Caucus Chair Pramila Jayapal (D-Wash.), Congressional Black Caucus Chair Joyce Beatty (D-Ohio), Congressional Hispanic Caucus Chair Raul Ruiz, M.D. (D-Calif.), and Congressional Asian Pacific American Caucus Chair Judy Chu (D-Calif.)--urge that a proposed $35 cap on a monthly supply of insulin be extended to those without health insurance. They write, "failure to do so will deepen health disparities and increase long-term healthcare costs."

The lawmakers emphasize that, with the price of insulin having risen more than 1,000 percent since 1999, affordability is a crisis for the 37.3 million Americans who have diabetes -- but it is especially dire for those without coverage. Two million people with diabetes don't have insurance, and more than one in four of those who need insulin have experienced a lapse in insurance coverage for at least 30 days in the past three years. Uninsured people with diabetes often pay over $1,000 per month for their insulin, and are roughly twice as likely to report that they cannot afford their diabetes medications compared to those who have insurance.

As the lawmakers write, the consequences are quite literally life and death: "Whether without insurance for an extended period of time or for 30 days due to life events such as job transitions or marriage, uninsured people with diabetes often pay over $1,000 per month for their insulin...Sadly, there are many tragic accounts of uninsured people with diabetes who could not afford their insulin and died as a result of insulin rationing."

Excluding uninsured people from a cap on out-of-pocket costs would also worsen racial disparities in our healthcare system. Black, Hispanic, and Asian Americans have both higher rates of diabetes than white Americans, and are less likely to have health insurance. As the letter notes, "A 2021 study in the Lancet demonstrated that within the diabetes community, 2.2 percent of white people were uninsured compared to 6.4 percent of Black people, 32.6 percent of Hispanic people, and 15.3 percent of Native American and Alaskan Native people." Extending the co-pay gap would also have significant savings for the healthcare system long term, since "patients with gaps in their health insurance in the past three years were five times more likely to end up in an emergency room or hospital while uninsured than while they were insured."

The lawmakers make clear that a universal cap on insulin costs could be accomplished either by using existing Medicaid payment structures to reimburse pharmacies or by establishing a fund in HHS that reimburses insurance providers and pharmacies. They conclude, "inclusion of uninsured people in insulin pricing legislation will help prevent new racial health disparities resulting from this legislation, curb future deaths of Americans due to insulin rationing, and decrease the likelihood of diabetes complications."

* * *

Dear Speaker Pelosi, Minority Leader McCarthy, Majority Leader Schumer, and Minority Leader McConnell,

We write to express grave concern with the exclusion of uninsured people in the proposed legislation to establish a $35 out-of-pocket cost caps on insulin and to urge you to include this population in these caps. Failure to do so will deepen health disparities and increase long-term healthcare costs. Moreover, we risk additional deaths from untreated and under-treated diabetes simply because of the outrageous price of insulin. Individuals with diabetes who require daily insulin injections risk dying if they lose access to insulin for even a few days.

The price of insulin has risen more than 1,000 percent since 1999, causing a dangerous affordability crisis in America. There are 37.3 million Americans with diabetes, including nearly 2 million uninsured people with diabetes. In addition to those uninsured for extended periods of time, 1 out of 4 privately-insured Americans with diabetes experienced at least one gap in insurance for at least 30 days in the past three years. Whether without insurance for an extended period of time or for 30 days due to life events such as job transitions or marriage, uninsured people with diabetes often pay over $1,000 per month for their insulin. Uninsured individuals are roughly twice as likely to report that they cannot afford their diabetes medications compared to those Americans with diabetes who have insurance.

Sadly, there are many tragic accounts of uninsured people with diabetes who could not afford their insulin and died as a result of insulin rationing. One such tragic and preventable story is that of Alec Smith, a 26-year-old who died from insulin rationing just one month after aging out of his mother's insurance and becoming uninsured. It is clear that the sky-high price of insulin poses a direct threat to the lives of many Americans with diabetes.

Diabetes disproportionately affects people of color, with the risk of having a diabetes diagnosis 77 percent higher among Black Americans, 66 percent higher among Hispanic Americans, and 18 percent higher among Asian Americans compared to white Americans. Additionally, people of color with diabetes are significantly more likely to be uninsured. A 2021 study in the Lancet demonstrated that within the diabetes community, 2.2 percent of white people were uninsured compared to 6.4 percent of Black people, 32.6 percent of Hispanic people, and 15.3 percent of Native American and Alaskan Native people. Therefore, legislation that caps the out-of-pocket cost of insulin only for people with private insurance or Medicare will leave many racial and ethnic groups behind and create a new racial health disparity in our health system, which is already fraught with many other disparities.

Including uninsured people in proposed insulin out-of-pocket caps will also decrease long-term healthcare spending. People with diabetes who are uninsured are a major driver of emergency room and hospital usage. Patients with gaps in their health insurance in the past three years were five times more likely to end up in an emergency room or hospital while uninsured than while they were insured. Further, uninsured patients are at an increased risk for poor health outcomes from diabetes including kidney failure, cardiac disease, and blindness. These poor outcomes result from lack of access to care and insulin needed to control diabetes. Establishing a $35 out-of-pocket cost cap for uninsured people with diabetes will decrease the rate of diabetes complications and correspondingly decrease future national health expenditures.

The $35 cap on out-of-pocket insulin costs could be expanded to include the uninsured in a number of ways. We suggest one of the following:

* The government use existing Medicaid payment structures to reimburse retail pharmacies for the difference between the list price and the $35 payment from uninsured people who fill their insulin prescriptions; or

* HHS creates a fund to reimburse health care providers and pharmacies for insulin disbursed to uninsured individuals, similar to the HRSA COVID-19 Uninsured Program.

We strongly support efforts to decrease the price of insulin and enable Americans with diabetes to afford their medication. We urge you to include the uninsured in the $35 out-of-pocket cost caps to any legislation addressing insulin pricing that Congress considers. Inclusion of uninsured people in insulin pricing legislation will help prevent new racial health disparities resulting from this legislation, curb future deaths of Americans due to insulin rationing, and decrease the likelihood of diabetes complications.

Thank you for your consideration. We look forward to working with you on this critical issue and voting on legislation that will cap insulin prices for all people with diabetes, regardless of their insurance status. Thank you for your attention to this important matter.

* * *

Original text here: https://pingree.house.gov/news/documentsingle.aspx?DocumentID=4279